Zimmer Biomet Chief Communications and Administration Officer Keri Mattox [Photo courtesy of Zimmer Biomet]
Zimmer Biomet (NYSE:ZBH) today announced additional responsibilities for Investor Relations SVP and Chief Communications Officer Keri Mattox.
Mattox’s new title at the Warsaw, Indiana-based orthopedics company is chief communications and administration officer. She will be responsible for “building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement and accessibility,” the company said in a news release.
Mattox will report to Chair, President and CEO Bryan Hanson, who said the new ESG function is essential “as we continue to focus on delivering on our mission to alleviate pain and improve the quality of life for people around the world.”
“Since joining Zimmer Biomet in January 2020, Keri has spearheaded our brand evolution, worked to build a best-in-class communications and IR function and expanded and publicly launched the Zimmer Biomet Foundation, overseeing the creation of our Team Member Relief Fund, Giving Center and local and global philanthropy activities,” Hanson said in the news release. “I am confident that in this expanded role, Keri will continue to raise ZB awareness and I look forward to partnering more closely with her as part of our ongoing evolution and transformation.”
Mattox was previously the global leader of integrated corporate communications at W2O Group (now known as Real Chemistry). Her responsibilities at the healthcare marketing and communications firm included “strategically shaping and expanding the firm’s global corporate communications, investor relations, crisis communications, M&A, board engagement and corporate social responsibility/foundation capabilities and offering,” Zimmer Biomet said.
The former newspaper reporter’s career also included serving as president of corporate and ivestor relations at AmerisourceBergen and executive leadership team level positions at Endo International and Auxilium Pharmaceuticals.